SEC Company Response from Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786) (RKTO) — Oct 23, 2019
Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786)
Date: Oct. 23, 2019 · CIK: 0001711786 · Accession: 0001213900-19-020932
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233954
Referenced dates: October 7, 2019
Letter
VIA EDGAR United States Securities and Exchange Commission Attention: Ada D. Sarmento Re: Hoth Therapeutics, Inc. Registration Statement on Form S-1 Filed September 26, 2019 File No. 333-233954
Dear Ladies and Gentlemen:
This letter sets forth responses on behalf of Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), to the comments received from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) set forth in your letter dated October 7, 2019 (“Comment Letter”) regarding the Company’s Registration Statement on Form S-1 (the “Registration Statement”).
For the convenience of the Staff, each comment from the Comment Letter corresponds to the numbered paragraphs in this letter and is restated prior to the response to such comment.
Registration Statement on Form S-1
General
Exclusive Forum, page 82
1. It appears that you have elected to incorporate certain information by reference into the prospectus, including your financial statements. Please provide the disclosure required by Item 12(a) of Form S-1.
Response:
The Company has revised disclosure in the Registration Statement to include the disclosure required by Item 12(a) of Form S-1.
Sincerely,
Hoth Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
HOTH THERAPEUTICS, INC.
1 Rockefeller Plaza, Suite 1039
New York, New York 10020
October 23, 2019
VIA EDGAR
United States Securities and Exchange Commission
100 F. Street, NE
Washington, DC 20549
Attention: Ada D. Sarmento
Christine Westbrook
Re:
Hoth Therapeutics, Inc.
Registration Statement on Form S-1
Filed September 26, 2019
File No. 333-233954
Dear Ladies and Gentlemen:
This letter sets forth
responses on behalf of Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), to the comments received from
the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) set forth in your
letter dated October 7, 2019 (“Comment Letter”) regarding the Company’s Registration Statement on Form S-1 (the
“Registration Statement”).
For the convenience
of the Staff, each comment from the Comment Letter corresponds to the numbered paragraphs in this letter and is restated prior
to the response to such comment.
Registration Statement on Form S-1
General
Exclusive Forum, page 82
1. It appears that you have elected
to incorporate certain information by reference into the prospectus, including your financial statements. Please provide the disclosure
required by Item 12(a) of Form S-1.
Response:
The Company has revised disclosure
in the Registration Statement to include the disclosure required by Item 12(a) of Form S-1.
Sincerely,
Hoth Therapeutics, Inc.
/s/ Robb Knie
By: Robb Knie
Title: Chief Executive Officer